Microbiology and Immunology

You are here

Publications

Found 14 results

Filters: Author is Barry, Clifton E [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

de Melo CSoares, Singh V, Myrick A, Simelane SB, Taylor D, Brunschwig C, Lawrence N, Schnappinger D, Engelhart CA, Kumar A et al.. 2021. Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.. J Med Chem. 64(1):719-740.

B

Boshoff HIM, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park T-H, Yun C-S, Schnappinger D, Ehrt S et al.. 2008. Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.. J Biol Chem. 283(28):19329-41.

Duckworth BP, Geders TW, Tiwari D, Boshoff HI, Sibbald PA, Barry CE, Schnappinger D, Finzel BC, Aldrich CC. 2011. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis.. Chem Biol. 18(11):1432-41.

D

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N et al.. 2018. Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.. J Med Chem. 61(22):9952-9965.

E

Park SWoong, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee K, Barry CE, Aldrich CC et al.. 2011. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression.. PLoS Pathog. 7(9):e1002264.

G

Kim J-H, O'Brien KM, Sharma R, Boshoff HIM, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC et al.. 2013. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.. Proc Natl Acad Sci U S A. 110(47):19095-100.

I

Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al.. 2026. Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.

Green SR, Harrison JR, Thompson S, Murugesan D, M Libardo DJ, Engelhart CA, Meshanni J, Fletcher D, Scullion P, Edwards D et al.. 2025. Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis.. ACS Infect Dis. 11(3):715-726.

Gold B, Zhang J, Quezada LLopez, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L et al.. 2022. Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.. ACS Infect Dis. 8(3):557-573.

M

Shi C, Geders TW, Park SWoong, Wilson DJ, Boshoff HI, Abayomi O, Barry CE, Schnappinger D, Finzel BC, Aldrich CC. 2011. Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobaterium tuberculosis.. J Am Chem Soc. 133(45):18194-201.

P

Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang H-J, Sutphen ML, Weiner DM, Dayao EK et al.. 2019. Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development.. Nat Commun. 10(1):4970.

S

Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn JA, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.. Nat Rev Microbiol. 7(12):845-55.

T

Nathan C, Barry CE. 2015. TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.

Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al.. 2021. The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.